RNA injection aims to control blood sugar in type 2 diabetes
NCT ID NCT07347080
First seen Jan 21, 2026 · Last updated May 23, 2026 · Updated 16 times
Summary
This early-stage study tests a single injection of CR059, a new RNA-based medicine, in 9 Chinese adults with type 2 diabetes. The main goal is to check safety and how the body processes the drug. Researchers will also measure its effect on blood sugar and immune response. This is not a cure; participants will still need ongoing diabetes management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Henan University of Science and Technology
RECRUITINGLuoyang, Henan, 310015, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.